Human Amnion Epithelial Cells for Prevention of Bronchopulmonary Dysplasia in Preterm Infants: A Safety Study
Phase 1
Recruiting
- Conditions
- Bronchopulmonary DysplasiaExtremely preterm birth
- Registration Number
- ACTRN12618000920291
- Lead Sponsor
- Monash Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the therapeutic effects of human amnion epithelial cells in preventing bronchopulmonary dysplasia in preterm infants?
How does the safety profile of human amnion epithelial cell therapy compare to standard-of-care treatments for bronchopulmonary dysplasia in extremely preterm infants?
What biomarkers are associated with response to human amnion epithelial cell therapy in the prevention of bronchopulmonary dysplasia?
What adverse events have been reported in phase 1 trials of human amnion epithelial cells for neonatal lung diseases?
Are there any combination therapies or competitor drugs being investigated alongside human amnion epithelial cells for bronchopulmonary dysplasia prevention in preterm infants?